| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160347.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160347.txt","company":"Tyra Biosciences, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160347.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_9960a026972b23eb","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160347.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:25:43.577463+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160347.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160347.txt","source_event_id":"evt_6cf6b0b7f319","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"c57f560c2e06ef6d","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-16","2026-04-17","2026-04-18","April 2022","December 2016","November 2021","October 2015","December 2016","2013","2015","2010","2012","February 2026","November 2025","January 2024","September 2022","September 2018","January 2021","June 2022","July 2025","July 2023","April 2025","August 2022","March 2023"],"entities":[{"asset_class":"equity","name":"Tyra Biosciences, Inc.","relevance":"primary","symbol":"TYRA","type":"issuer"},{"asset_class":"person","name":"Habib J. Dable","relevance":"primary","symbol":"","type":"individual"},{"asset_class":"other","name":"Nominating and Corporate Governance Committee","relevance":"secondary","symbol":"","type":"committee"},{"asset_class":"other","name":"RA Capital Management, L.P.","relevance":"background","symbol":"","type":"organization"},{"asset_class":"other","name":"Acceleron Pharma Inc.","relevance":"background","symbol":"","type":"organization"},{"asset_class":"other","name":"Merck","relevance":"background","symbol":"","type":"organization"}],"event_type":"listing","information_gaps":["The filing\u2019s SEC \u201cItem\u201d section(s) are not explicitly captured in the provided text (the excerpt includes narrative but does not show the Item number labels).","The signal indicates a \u201cdelta\u201d vs prior known state, but no prior state content is provided here, so the exact change relative to prior disclosures cannot be verified beyond the contents of this 8-K.","The excerpt ends mid-sentence (\u201cThere are no arrangements or understandings\u2026 w\u201d), so any additional required disclosures after that point are not included in the provided text."],"key_facts":["Tyra Biosciences filed a Form 8-K with a date of report of April 16, 2026.","On April 16, 2026, the board approved an increase in the number of authorized directors from nine to ten.","On April 16, 2026, the board appointed Habib J. Dable as a Class II director.","Mr. Dable\u2019s initial term is stated to expire at the Company\u2019s 2026 annual meeting of stockholders.","In connection with the appointment, Mr. Dable was granted options to purchase 44,400 shares of the Company\u2019s common stock.","The options\u2019 exercise price is stated to equal the fair market value of the Company\u2019s common stock on the date of grant.","The options are stated to vest in substantially equal monthly installments over 36 months following the date of grant.","Mr. Dable will receive cash compensation for service on the board and committees under the Company\u2019s Non-Employee Director Compensation Program.","Mr. Dable entered into the Company\u2019s standard form of indemnification agreement (form filed with the Company\u2019s most recent annual report on Form 10-K)."],"numeric_claims":[{"label":"authorized directors increased from","value":"9 to 10"},{"label":"Class II director initial term expires","value":"2026 annual meeting of stockholders"},{"label":"options granted (shares)","value":"44,400"},{"label":"option vesting period","value":"36 months"},{"label":"monthly vesting installments","value":"substantially equal monthly installments over 36 months"},{"label":"director age (stated)","value":"56"}],"primary_claim":"On April 16, 2026, Tyra Biosciences\u2019 board approved an increase in authorized directors from nine to ten and appointed Habib J. Dable as a Class II director with an initial term expiring at the 2026 annual meeting of stockholders.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Tyra Biosciences filed a Form 8-K reporting that its board increased authorized directors from nine to ten and appointed Habib J. Dable as a Class II director on April 16, 2026.","topics":["8-K","board of directors","director appointment","corporate governance","executive/board compensation","biopharmaceuticals"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Tyra Biosciences, Inc. \u00b7 Filed 20260417","ticker":"TYRA","tickers":["TYRA"],"title":"TYRA filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160347.txt"}... |